← Back to Search

Tele-rheumatology for Rheumatic Diseases

N/A
Waitlist Available
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of rheumatic disease (e.g. rheumatoid arthritis, SLE)
Be older than 18 years old
Must not have
Unstable rheumatic disease that needs in-person visits (e.g. recent diagnosis of severe lupus nephritis)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36-72 hours post visit after the first visit
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the effectiveness of tele-rheumatology visits for high risk people living with rheumatic and musculoskeletal disease, compared to in-person usual care.

Who is the study for?
This trial is for people with rheumatic diseases like rheumatoid arthritis or lupus who are stable enough to not require in-person visits. It's especially aimed at those using immunosuppressive drugs and from socially vulnerable populations. However, it excludes individuals with unstable conditions needing face-to-face care or those without access to a phone.
What is being tested?
The study is testing the effectiveness of tele-rheumatology (remote medical consultations via phone or internet) compared to usual in-person care for patients with rheumatic diseases during the COVID-19 crisis. It's a randomized experiment aiming to provide safe and equitable care.
What are the potential side effects?
Since this trial involves remote consultations rather than medication, traditional side effects aren't expected. However, there may be technical issues or communication barriers that could affect the quality of care received.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a rheumatic disease like rheumatoid arthritis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a severe rheumatic condition requiring frequent doctor visits.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36-72 hours post visit after the first visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36-72 hours post visit after the first visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient satisfaction
Secondary study objectives
Patient preference

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Usual Care first visit and Tele-rheumatology second visitExperimental Treatment1 Intervention
Participants randomized to this visit will receive a usual care visit first.
Group II: Tele-rheumatology first visit and Usual Care second visitExperimental Treatment1 Intervention
Participants randomized to this visit will receive a tele-rheumatology visit first.

Find a Location

Who is running the clinical trial?

Rheumatology Research FoundationOTHER
11 Previous Clinical Trials
7,411 Total Patients Enrolled
1 Trials studying Rheumatic Diseases
5,000 Patients Enrolled for Rheumatic Diseases
University of Alabama at BirminghamLead Sponsor
1,641 Previous Clinical Trials
2,331,498 Total Patients Enrolled
3 Trials studying Rheumatic Diseases
1,765 Patients Enrolled for Rheumatic Diseases
University of California, San FranciscoOTHER
2,580 Previous Clinical Trials
15,176,848 Total Patients Enrolled
1 Trials studying Rheumatic Diseases
65 Patients Enrolled for Rheumatic Diseases

Media Library

Tele-rheumatology Clinical Trial Eligibility Overview. Trial Name: NCT04704544 — N/A
Rheumatic Diseases Research Study Groups: Usual Care first visit and Tele-rheumatology second visit, Tele-rheumatology first visit and Usual Care second visit
Rheumatic Diseases Clinical Trial 2023: Tele-rheumatology Highlights & Side Effects. Trial Name: NCT04704544 — N/A
Tele-rheumatology 2023 Treatment Timeline for Medical Study. Trial Name: NCT04704544 — N/A
~160 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top